Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.25 - $0.45 $4,850 - $8,730
-19,400 Reduced 46.75%
22,100 $9,000
Q4 2022

Feb 14, 2023

SELL
$0.2 - $0.33 $320 - $528
-1,600 Reduced 3.71%
41,500 $9,000
Q3 2022

Nov 14, 2022

BUY
$0.35 - $1.1 $8,540 - $26,840
24,400 Added 130.48%
43,100 $16,000

About CHEMBIO DIAGNOSTICS, INC.


  • Ticker CEMI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,224,600
  • Description
  • Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...
More about CEMI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.